Overview

Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Assessment of Intubation conditions following administration of neuromuscular blocking agents; BX1000 (investigational) or rocuronium (active control).
Phase:
Phase 2
Details
Lead Sponsor:
Baudax Bio
Treatments:
Bromides
Rocuronium